GlassScriptPhysician profile
Catherine Spiker
NPI 1760744726
$18,240.73
in general payments reported to CMS, 2019-2025
68 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,820 · 2020: $2,987 · 2021: $3,263 · 2022: $2,412 · 2023: $2,126 · 2024: $2,637 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,758.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,156.48 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,771.29 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,598.15 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $1,331.31 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $782.67 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $770.25 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $711.99 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $694.34 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $622.96 | 2019-2024 | Ofev |
| Lilly USA, LLC | $472.54 | 2019-2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $471.77 | 2019-2025 | |
| Amgen INC. | $428.78 | 2019-2024 | Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $415.33 | 2019-2025 | Xifaxan |
| Allergan, INC. | $397.97 | 2019-2021 | |
| Astellas Pharma US INC | $353.25 | 2019-2025 | Veozah, Myrbetriq |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $327.18 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $326.61 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $319.71 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $283.69 | 2021-2025 | |
| Lundbeck LLC | $261.99 | 2022-2025 | Rexulti, Vyepti |
| Neurocrine Biosciences, INC. | $261.02 | 2023-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $259.00 | 2019-2025 | Vaxneuvance, Gardasil 9, Vaxelis |
| E.R. Squibb & Sons, L.L.C. | $225.91 | 2019-2025 | Eliquis, Camzyos |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $202.08 | 2022-2025 | Caplyta |
| Amarin Pharma, INC. | $189.30 | 2019-2022 | |
| Mylan Specialty L.P. | $161.51 | 2019-2024 | Yupelri |
| Alkermes, INC. | $151.67 | 2022-2024 | Lybalvi, Aristada, Aristada Initio |
| Dexcom, INC. | $143.35 | 2021-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $135.47 | 2019-2022 | |
| Abbott Laboratories | $132.58 | 2019-2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $129.24 | 2020-2023 | Nexletol |
| Cardiovascular Systems INC. | $121.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $120.76 | 2019-2022 | |
| Shield Therapeutics INC | $118.90 | 2023-2025 | Accrufer |
| Axsome Therapeutics, INC. | $117.89 | 2023-2025 | Auvelity |
| Penumbra, INC. | $109.55 | 2022 | |
| Sumitomo Pharma America, INC. | $104.31 | 2023-2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $93.10 | 2022 | |
| Insulet Corporation | $79.64 | 2021-2024 | Omnipod |
| Corcept Therapeutics | $69.60 | 2025 | Korlym |
| Genentech USA, INC. | $68.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $63.44 | 2019-2024 | Austedo Xr |
| Nestle Healthcare Nutrition INC. | $57.51 | 2021-2023 | |
| Arbor Pharmaceuticals, INC. | $54.89 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $53.31 | 2024-2025 | Fanapt, Hetlioz |
| Xeris Pharmaceuticals, INC. | $40.29 | 2025 | Gvoke Hypopen |
| Baxter Healthcare | $38.14 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Aimmune Therapeutics, INC. | $37.48 | 2025 | Zenpep |
| Ardelyx, INC. | $35.74 | 2024-2025 | Ibsrela |
| Ucb, INC. | $34.97 | 2024 | Nayzilam |
| Inspire Medical Systems, INC. | $33.37 | 2025 | Inspire |
| Ironwood Pharmaceuticals, INC | $28.21 | 2019-2021 | |
| Cequr Corporation | $25.93 | 2024 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $23.58 | 2021-2022 | |
| Argenx US, INC. | $20.77 | 2024 | Vyvgart Hytrulo |
| Boston Scientific Corporation | $19.20 | 2025 | Watchman Access System |
| Phathom Pharmaceuticals, INC. | $18.69 | 2025 | Voquezna |
| Verona Pharma, INC. | $18.47 | 2025 | Ohtuvayre |
| Abiomed | $17.51 | 2021 | |
| Biowound Solutions, INC. | $16.29 | 2025 | Bio-Connekt |
| Seqirus USA INC | $15.12 | 2024 | Fluad, Flucelvax |
| Ibsa Pharma INC. | $14.94 | 2022 | |
| Medtronic, INC. | $14.09 | 2022 | |
| Antares Pharma, INC. | $13.88 | 2024 | Xyosted |
| Tolmar, INC. | $13.81 | 2024 | |
| Integra Lifesciences Corporation | $13.42 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Eisai INC. | $12.93 | 2020 | |
| Horizon Therapeutics Plc | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Spiker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.